Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee Joint

A 2-stage, Phase 2a Study to Evaluate the Efficacy, Safety, and Tolerability of OLP-1002 Subcutaneous Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in a Hip and/or Knee Joint

The study is designed to evaluate the efficacy, safety and tolerability of OLP-1002 Subcutaneous (SC) injections for reducing moderate to severe pain due to osteoarthritis in a hip and/or knee joint.

Study Overview

• Status: Recruiting
• Conditions: Osteoarthritis
• Intervention / Treatment: Drug: OLP-1002

Detailed Description

The study consists of two Stages (Stage 1 and Stage 2)

Stage 1: It is an open-label, dose-finding study employing a single ascending dose design to determine appropriate dose level starting dose of OLP-1002 for Stage 2 of the study in participants with moderate to severe pain due to osteoarthritis in a hip and/or knee joint.

Stage 1 consists of following:

• Screening period: up to 15 days (± 2 days) (defined as Day -23 to -9)
• Washout period: 5 days (± 1 day) (defined as Day -8 to -4)
• Baseline period: 3 days (± 1 day) (defined as Day -3 to -1)
• Treatment period: 1 day (defined as Day 1): participants will be subcutaneously administered a single dose of OLP-1002 at the assigned dose level (1 μg, 3 μg, 10 μg, 25 μg, 50 μg, 80 μg)
• Follow-up period: 30 days (± 5 days) (defined as Day 2 to 30)

Approximately 30 participants will be enrolled in Stage 1 of the study

Stage 2: The study will be a double-blind, placebo-controlled, parallel-arm study of up to 2 selected single doses of OLP-1002 to evaluate the efficacy of OLP-1002 in the treatment of pain in participants with moderate to severe pain due to osteoarthritis in a knee or hip joint.

Dose levels for Stage 2 will be 1 μg and 2 μg of OLP-1002. Dose selection was based on the conclusions drawn from the internal efficacy data review analysis conducted by Sponsor from data collected in Stage 1 of the study.

Stage 2 consists of following:

• Screening Period: up to 14 days (± 2 days)
• Baseline Period: 3 days (± 1 day)
• Treatment: 1 day (± 2 days)
• Follow-up period: 42 days from last dose, D43 (± 5 days)

Approximately 90 participants will be enrolled in Stage 2 of the study

• Study Type: Interventional
• Enrollment (Anticipated): 120
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Toula Papadodimitrakis; Phone Number: +61 03 9491 8505; Email: Toula.Papadodimitrakis@novotech-cro.com

Study Locations

• Australia
  • New South Wales
    • Kotara, New South Wales, Australia, 2289
      • Not yet recruiting
      • Novatrials
      • Principal Investigator: Oscar Cumming, MD
    • Sydney, New South Wales, Australia, 2019
      • Recruiting
      • Emeritus Research
      • Principal Investigator: Paul Bird, MD
  • Queensland
    • Taringa, Queensland, Australia, 4068
      • Not yet recruiting
      • AusTrials
      • Principal Investigator: Florence Tiong, MD
    • Wellers Hill, Queensland, Australia, 4121
      • Not yet recruiting
      • AusTrials
      • Principal Investigator: Ferdinandus De Looze, MD
  • Victoria
    • Melbourne, Victoria, Australia, 3124
      • Recruiting
      • Emeritus Research
      • Contact: Andrew Ostor, MD
      • Contact: Oscar Tunjic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Willing and able to provide written informed consent prior to any study-related procedures being performed in accordance with Good Clinical Practice (GCP), International Council for Harmonisation (ICH) and local regulations.
2. Male or female aged ≥ 35 years to ≤ 70 years as of the date of enrolment into the study
3. No history of cardiac disease including arterial or venous thrombi, cardiac arrhythmia, myocardial infarction, admission to hospital for unstable angina, cardiac angioplasty or stent implantation within 90 days prior to Screening.
4. Body mass index (BMI) ≥ 18 kg/m2 < 40 kg/m2 at Screening.

5. Pain in hip or knee joints, every day for at least 1-month during the 3 months prior to Screening.

   Note: Participants must have a pain severity score of ≥ 5 based on the 3-day mean VAS score during the Baseline Period and must have recorded the pain score every day during the Baseline Period.

6. Diagnosis of Osteoarthritis (OA) of the index hip or knee: moderate to severe osteoarthritis, based on American College of Rheumatology (ACR) criteria with Kellgren Lawrence x-ray grade of at least 2, as diagnosed by the radiologist or rheumatologist.
7. Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain score of ≥ 10 out of 20 in the index hip or knee at Screening.
8. Willing and able to provide their historical use of nonsteroidal anti-inflammatory drugs (NSAIDs) either over-the-counter (OTC) per recommendation of a physician or prescribed during the past 6 months (the pain in the target knee and/or hip required).

9. Women of childbearing potential (WOCBP) must be non-pregnant and non-lactating, and must use acceptable, highly effective double contraception from Screening until 90 days after the last dose of IP. Double contraception is defined as a condom AND one other form of the following:

   1. Established hormonal contraception (for example, approved oral contraceptive pills [OCPs], long-acting implantable hormones, injectable hormones),
   2. A vaginal ring or an intrauterine device (IUD), or
   3. Documented evidence of surgical sterilisation at least 6 months prior to Screening (eg, tubal occlusion, hysterectomy, bilateral salpingectomy, or bilateral oophorectomy for women or vasectomy for men [with appropriate post-vasectomy documentation of the absence of sperm in semen] provided the male partner is a sole partner).

   Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not considered highly effective methods of birth control. A participant's treatment is acceptable.

10. Women not of childbearing potential must be postmenopausal for ≥ 12 months. Post-menopausal status will be confirmed through testing of FSH levels ≥ 40 IU/L at Screening for amenorrhoeic female participants. Female participants who are abstinent from heterosexual intercourse will also be eligible.

    Female participants who are in a same-sex relationship are not required to use contraception.

11. Male participants must be surgically sterile (>30 days since vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a WOCBP, the participant and his partner must be surgically sterile (eg, tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or using an acceptable, highly effective contraceptive method from Screening until 90 days after the last dose of IP. Acceptable methods of contraception include the use of condoms and the use of an effective contraceptive for the female partner that includes: OCPs, long-acting implantable hormones, injectable hormones, a vaginal ring or an IUD.

    Male participants with a same-sex partner (abstinence from penile-vaginal intercourse) are eligible when this is their preferred and usual lifestyle.

12. WOCBP must have a negative pregnancy test at Screening and Day 1 and be willing to have additional pregnancy tests as required throughout the study.
13. Male participants must agree not donate sperm for at least 90 days after the last dose of IP.
14. Agree to maintain their usual levels of activity throughout the course of the study.
15. Willing to abstain from other intra-articular treatments of the joint and any joint surgery while on the study.
16. Able to comply with study procedures, including the completion of daily questionnaires.
17. Subjects suffering from moderate to severe pain secondary to diagnosed OA of the knee and/or hip joint with fit for range of age & BMI will be included with proof of COVID 19 full vaccinations and intention of the participation in the study.

Exclusion Criteria:

1. Known history or current symptomatic heart failure as per New York Heart Association (NYHA) classes II-IV, including unstable angina, myocardial infarction, serious cardiac arrhythmia, cerebral vascular accident, coronary/peripheral artery bypass graft surgery, transient ischaemic attack, or pulmonary embolism within 90 days prior to Screening.

   Participants with small pulmonary embolism not thought to put participants at higher risks of AEs may be allowed on a case-by-case basis in discussion with Sponsor.

2. History of malignancy except for basal cell carcinoma with successful removal, ALL other non-melanoma skin cancers excised successfully more than 2 years ago, and cervical intraepithelial neoplasia that has been successfully cured more than 5 years prior to the Screening Period.

3. Any of the following:

   1. Intra-articular treatment injections (including but not limited to corticosteroids, hyaluronic acid, platelet rich plasma, BOTOX®, local anaesthetics) within 3 months prior to the Screening period,
   2. QTcF > 450 ms confirmed by repeat ECG measurement,
   3. QRS duration > 120 ms confirmed by repeat ECG measurement,
   4. PR interval > 220 ms confirmed by repeat ECG measurement,
   5. Findings which would make QTc measurements difficult or QTcF data uninterpretable as per Investigator discretion,
   6. History of additional risk factors for torsades de pointes (eg, heart failure (class III/IV according to the New York Heart Association [NYHA]), hypo/hyperkalaemia, family history of long QT syndrome), or
   7. Taking any arrhythmic or arrythmia evoking agents.

4. Unable or unwilling to cease the use of all pain reducing medications and all pain reducing devices, prescription or otherwise, as of the first day of the study Baseline Period and until the End of Study visit. These include all topical and oral opioid and antiinflammatory medications, herbal and homeopathic remedies, electrostimulation therapy (EST) and neuromuscular re-education (NMRE). This excludes the use of paracetamol provided that a participant is able and willing to utilise paracetamol/acetaminophen (2 g/day) as rescue medication or up to 4 g/day for intolerable pain following consent from the PI (or designee) without prior approval from the Sponsor, as of the first day of the study, Baseline Period, and until the End of Study visit.

   Note: The participant may continue taking usual medication for maintenance of health.

5. Any of the following laboratory abnormalities within 14 days of Day 1:

   • Platelet count < 100,000 cells/mm3.
   • Total neutrophil count < 1500 cells/mm3.
   • Serum creatinine ≥ 1.5 x upper limit of normal (ULN).
   • Alanine aminotransferase (ALT) > 3.0 x ULN).
   • Aspartate aminotransferase (AST) > 3.0 x ULN.
   • Alkaline phosphatase > 2.0 x ULN.
   • Bilirubin > 1.5 x ULN.
   • Aural Temperature ≥ 38 degree Celsius or other evidence of an infection.

6. History of alcoholism, substance abuse or dependence during the 12 months prior to Screening:

   1. During the study, alcohol consumption of > 21 units per week for males and > 14 units per week for females will not be allowed. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.
   2. Positive urine drug screen (confirmed by repeat) or alcohol consumption (self-report) higher than the permissible limit, as mentioned above, at Screening or Baseline shall be excluded from the study.
7. Has an allergy or hypersensitivity to OLP-1002 or its constituents.
8. Female participants who are pregnant at Screening or are planning on becoming pregnant, or are currently breastfeeding up to 90 days from end of study.
9. Any medical condition or comorbidities as assessed by the Investigator, that could adversely impact study participation or safety, conduct of the study, or interfere with pain assessments.
10. Active skin conditions such as dermatitis, allergy, eczema, psoriasis, or abnormal skin healing. This criterion is applied in general and is not limited to the active disease at the planed injection site.
11. Tattoos, scars, or moles that in the opinion of the Investigator are likely to interfere with dosing or study assessments at any of the potential injection sites.
12. Depression of moderate or greater severity as assessed by the Investigator or via the Patient Health Questionnaire (PHQ-9 ≥10) at the Screening visit.
13. History of psychotic symptoms, whether controlled or not and/or requiring antipsychotic treatment, or history of a suicidal attempt/s within 180 days prior to Screening.
14. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndromerelated illness, acute or history of chronic hepatitis B or C. Positive tests for HIV-1 or HIV-2 antibodies, hepatitis B surface antigen, or hepatitis C antibodies at Screening.
15. Concurrent medical or arthritic conditions that could interfere with evaluation of the index joint including fibromyalgia, rheumatoid arthritis, or other inflammatory arthropathies affecting the joint eg, sciatica, diabetic neuropathy, multiple sclerosis.
16. Has undergone arthroscopic or open surgery to the joint within 180 days of Screening visit.
17. Has undergone replacement surgery of the treatment joint within 180 days of Screening visit.
18. The presence of surgical hardware /medical device or other foreign bodies in the treatment joint within 180 days of Screening visit.

19. Use or intend to use any prescription medications/products other than those medications for health conditions (eg, hypertension, diabetes or other disease), within 14 days prior to the Screening visit until the EOS (End of Study) Visit, unless deemed acceptable by the Investigator (or designee).

    Note: Prescription medication is permitted except for pain control, if deemed acceptable by the Investigator (or designee).

20. Use or intend to use slow-release medications/products considered to still be active within 14 days prior to the Screening visit until the EOS Visit, unless deemed acceptable by the Investigator (or designee).
21. Receipt of blood products within 60 days prior to the Screening visit until the EOS Visit.
22. Donation of blood from 90 days prior to Screening until the EOS Visit, plasma from 14 days prior to Screening until the EOS Visit, or platelets from 42 days prior to Screening until the EOS Visit.
23. Poor peripheral venous access.
24. Is a Sponsor employee.
25. Has participated in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days or 5 half-lives of the IP, whichever is longer, prior to the Screening visit.
26. Has participated in any trial of a device, supplement, cognitive/behavioural therapy, physiotherapy or active exercise study within 30 days prior to the Screening visit.
27. Has previously received any dose of OLP-1002.
28. In the opinion of the Investigator (or designee), should not participate in this study.
29. Subjects who have history of or current serious illness with cardiac, vascular, cancer, infectious, mental, and laboratory abnormality will be excluded from this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

9

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Stage 1: Arm 1 (OLP-1002, 1 μg); Participants will receive once single dose of 1 μg OLP-1002 on Day 1 Mode of Administration: subcutaneously injection	Drug: OLP-1002; Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1. Each participant will receive one single dose of OLP-1002 by subcutaneous injection. Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo. Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.; Other Names: Diluent (Placebo) - Only for Stage 2
Experimental: Stage 1: Arm 2 (OLP-1002, 3 μg); Participants will receive once single dose of 3 μg OLP-1002 on Day 1 Mode of Administration: subcutaneously injection	Drug: OLP-1002; Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1. Each participant will receive one single dose of OLP-1002 by subcutaneous injection. Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo. Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.; Other Names: Diluent (Placebo) - Only for Stage 2
Experimental: Stage 1: Arm 3 (OLP-1002, 10 μg); Participants will receive once single dose of 10 μg OLP-1002 on Day 1 Mode of Administration: subcutaneously injection	Drug: OLP-1002; Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1. Each participant will receive one single dose of OLP-1002 by subcutaneous injection. Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo. Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.; Other Names: Diluent (Placebo) - Only for Stage 2
Experimental: Stage 1: Arm 4 (OLP-1002, 25 μg); Participants will receive once single dose of 25 μg OLP-1002 on Day 1 Mode of Administration: subcutaneously injection	Drug: OLP-1002; Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1. Each participant will receive one single dose of OLP-1002 by subcutaneous injection. Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo. Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.; Other Names: Diluent (Placebo) - Only for Stage 2
Experimental: Stage 1: Arm 5 (OLP-1002, 50 μg); Participants will receive once single dose of 50 μg OLP-1002 on Day 1 Mode of Administration: subcutaneously injection	Drug: OLP-1002; Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1. Each participant will receive one single dose of OLP-1002 by subcutaneous injection. Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo. Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.; Other Names: Diluent (Placebo) - Only for Stage 2
Experimental: Stage 1: Arm 6 (OLP-1002, 80 μg); Participants will receive once single dose of 80 μg OLP-1002 on Day 1 Mode of Administration: subcutaneously injection	Drug: OLP-1002; Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1. Each participant will receive one single dose of OLP-1002 by subcutaneous injection. Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo. Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.; Other Names: Diluent (Placebo) - Only for Stage 2
Experimental: Stage 2: Arm 1 (OLP-1002, 1μg); Participants will be randomised to receive single dose of 1μg OLP-1002 on Day 1 Mode of Administration: subcutaneously injection	Drug: OLP-1002; Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1. Each participant will receive one single dose of OLP-1002 by subcutaneous injection. Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo. Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.; Other Names: Diluent (Placebo) - Only for Stage 2
Experimental: Stage 2: Arm 2 (OLP-1002, 2μg); Participants will be randomised to receive single dose of 2μg OLP-1002 on Day 1 Mode of Administration: subcutaneously injection	Drug: OLP-1002; Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1. Each participant will receive one single dose of OLP-1002 by subcutaneous injection. Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo. Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.; Other Names: Diluent (Placebo) - Only for Stage 2
Placebo Comparator: Stage 2: Arm 3 (Placebo); Participants will be randomised to receive single dose of Placebo on Day 1 Mode of Administration: subcutaneously injection	Drug: OLP-1002; Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1. Each participant will receive one single dose of OLP-1002 by subcutaneous injection. Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo. Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.; Other Names: Diluent (Placebo) - Only for Stage 2

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Stage 1: Safety and tolerability of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through treatment related adverse events	Number of participants with treatment-related adverse events as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) criteria, v5.0.	From baseline to end of study treatment up to 30 days
Stage 2: Safety and tolerability of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through physical examination abnormalities.	Any abnormalities in the body System observed by the study physician in general appearance, Ears/Eyes/Nose/Throat/Thyroid, Head, Heart, Lungs, Abdomen, Skin, Neurological, Extremities, Back, Neck, Lymph Nodes, Dentition, Nusculoskeleton. For example,; Vital signs: out of range of normal BP systolic BP (lower than 90 and higher than 140), diastolic BP (lower than 40 and higher than 90), PR (50 -100), RR (10-20), BT(96-100 deg F); abnormal clinical exam noted by physical examining investigator.; out of range of normal criteria of ECG parameters.	From Baseline, Day 1 (post dose), 4, 8, 15, 22, 29, 36, 43 or End of Study visit
Stage 1: Safety and tolerability of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through vital signs- pulse rate	Measured by result of the vital signs- pulse rate	From baseline to end of study treatment up to 30 days
Stage 1: Safety and tolerability of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through vital signs- blood pressure	Measured by result of the Vital Sign- blood pressure (systolic and diastolic)	From baseline to end of study treatment up to 30 days
Stage 1: Safety and tolerability of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through vital signs- respiratory rate	Measured by result of the vital signs- respiratory rate	From baseline to end of study treatment up to 30 days
Stage 1: Safety and tolerability of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through vital signs- oral aural temperature	Measured by result of the vital signs- oral aural temperature	From baseline to end of study treatment up to 30 days
Stage 1: Safety and tolerability of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through changes in BMI.	Measured by body weight in kilograms (kg) and body height (centimetres) and body weight (kilograms). BMI will be calculated by dividing the participant's body weight in kilograms by the participant's height in meters squared (kg/m2).	From screening visit, Day 1 and Day 30 or End of Study visit
Stage 1: Safety of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through injection site reactions.	The number of adverse events on injection site reaction per arms will be measured. Measured by severities or size of erythema, tenderness, bruise, and swelling will be recorded as the injection site reactions. Also, the number and rate of participants with any TEAEs will be recorded.	Stage 1: From baseline to end of study treatment up to 30 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through injection site reactions.	The number of adverse events on injection site reaction per arms will be measured. Measured by severities or size of erythema, tenderness, bruise, and swelling will be recorded as the injection site reactions. Also, the number and rate of participants with any TEAEs will be recorded.	Stage 2 : From Day 1 (post dose), 4, 8, 15, 22, 29, 39, and 43 or End of Study visit
Stage 1: Safety and tolerability of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through clinical Biochemistry results	Measured by clinically significant changes in Biochemistry results	From baseline to end of study treatment up to 30 days
Stage 1: Safety and tolerability of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through clinical Haematology results	Measured by clinically significant changes in Haematology results	From baseline to end of study treatment up to 30 days
Stage 1: Safety and tolerability of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through clinical Urinalysis results	Measured by clinically significant changes in Urinalysis results	From baseline to end of study treatment up to 30 days
Stage 1: Safety and tolerability of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in knee and/or hip joint through Electrocardiogram (ECG), start of atrial depolarization to start of ventricular depolarization (PR interval).	Measured by PR interval in ECG	From screening visit till the end of the study visit up to 30 days
Stage 1: Safety and tolerability of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through Electrocardiogram (ECG) combination of the Q wave, R wave and S wave (QRS complex)	Measured by QRS complex result in ECG	From screening Visit till the end of the study visit up to 30 days
Stage 1: Safety and tolerability of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through Electrocardiogram (ECG), time from the start of the Q wave to the end of the T wave (QT interval).	Measured by QTcF result in ECG	From screening visit till the end of the study visit up to 30 days
Stage 2: Efficacy of single dose of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through changes in Western Ontario and McMaster Osteoarthritis Index (WOMAC)	Measured by Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale	From Screening visit, Day 1 (predose), Day 4, 8, 15, 22, 29, 39 and 43 or End of Study visit
Stage 2: Efficacy of single dose of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through changes in Visual Analogue Scale (VAS) pain score.	Measured by Visual Analogue Scale (VAS) pain score	From Baseline, Day 1 (post dose), 4, 8, 15, 22, 29, 39 and 43 or End of Study visit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Stage 1: To evaluate the efficacy of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through Brief Pain Inventory questionnaire	Brief Pain Inventory-Short Form (BPI-SF) is a 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. Patient's pain improvement will be assessed after administration of OLP-1002 on a 0 to 10 scale with 0 indicating 'no pain' and 10 indicating 'pain as worse' to assess daily pain scores.	Monitored on Day 1, 4, 8, 15, 30
Stage 1: To evaluate the efficacy of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through Patient Global Impression of Change questionnaire (PGIC)	Patient's pain improvement will be evaluated based on changes in PGIC questionnaire after administration of OLP-1002 into patient with Osteoarthritis to evaluate the condition of subjects activity limitations, symptoms, emotions and overall quality of life. Patient has to chose one answer to 7 questions, each question is measured on a scale from 1 (no change/or condition has gotten worse) to 7 (condition a great deal better/considerable improvement).	Monitored on Day 4, 15 and 30
Stage 1: To evaluate the efficacy of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through Symptom and Quality of Life questionnaires of the KOOS.	Symptom & Quality of Life of a patient with painful Osteoarthritis will be measured by Knee Injury and Osteoarthritis Outcome Score (KOOS): For questions S1,2,3 in Symtom, using "Never (0), Rarely (1), Sometimes (2), Often (3), Always (4)" For S4,5 in Symptom, using " Always (0), Often (1), Sometimes (2), Rarely (3), Never (4)". For Quality of Life, It comes with corresponds to "Never (0), Monthly (1), Weekly (2), Daily (3), Constantly (4)" or " Not at all (0), Mildly (1), Moderately (2), Severely (3), Totally or extremely (4)".	Monitored on Day 1, 8, 15, 30
Stage 1: To evaluate the efficacy of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through Symptom and Quality of Life questionnaires of the HOOS.	Symptom & Quality of Life of a patient with painful Osteoarthritis will be measured by Hip Injury and Osteoarthritis Outcome Score (HOOS): For Symptom, using "Never (0), Rarely (1), Sometimes (2), Often (3), Always (4)" or For Quality of Life, it comes with corresponding to "never (0), monthly (1), weekly (2), daily (3), constantly (4)" or "Not at all (0), Mild (1), Moderately (2), Severely (3), Totally or extremely (4)".	Monitored on Day 8, 15, 30
Stage 1: To evaluate the efficacy of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through Western Ontario McMaster Osteoarthritis Index (WOMAC)	Measured by Western Ontario and McMaster Osteoarthritis Index (WOMAC) with the pain, stiffness and physical function subscales. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 4 (highest pain/ highest stiffness/ lowest function).	From baseline to end of study treatment up to Day 1, Day 4, Day 8, Day 15, Day 30
Stage 1: To evaluate the efficacy of OLP-1002 in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through Visual Analogue Scale (VAS)	Measured by worst daily pain intensity score on a 0 to 10 VAS scale with 0 indicating 'no pain' and 10 indicating 'pain as worse' to assess daily pain scores. Participants will be provided with the Patient Diary to capture daily pain intensity in a 24 hour period.	From baseline to Day 4, 8, 15 and 30
Stage 1: To evaluate maximum plasma concentration of OLP-1002 in 1 hour post administration in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint	The previous phase 1 and 1b studies show that the practical detectable LLOQ with the currently available technique is limited to 1 nanogram/ml and LOD is 0.2 nanogram per milliter of plasma. Because of that, collecting blood samples with high dosing arms (80 mcg single dose, 160. mcg single dose, 40x5 doses, 80x5 doses) to measure OLP-1002's blood concentrating level for PK analysis method development for future OLP-1002 clincial trials. So, pK full evaluation is not available for OLP-1002 with very tiny dosing and blood concentration of OLP-1002 will be measured only in 25 mcg, 50 mcg, and 80 mcg dosing arms in stage 1.	Blood sample taken 1-hour post OLP-1002 administration on Day 1
Stage 1: Efficacy of OLP-1002 doses in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through a reduction in the use of allowed rescue pain medication	Compared with the Baseline at least a 50% reduction in the use of allowed rescue pain medication as an efficacy measure of OLP-1002 in each dose arm	During Days 1 (postdose) to 4, Days 5 to 8, Days 9 to 15 and Days 16 to 30
Stage 2: Efficacy of OLP-1002 doses in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through a reduction in the use of allowed rescue pain medication	Compared with the rescue medication usage in each dose arm at least a 50% reduction in the use of allowed rescue pain medication as an efficacy measure of OLP-1002	From baseline to Day 1 (pre dose and post dose) ,4 ,8 ,15 ,22 ,29 ,36, and 43 or Early End of Study visit
Stage 1: Efficacy of OLP-1002 doses in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through average use of rescue pain medication	Measured by the mean (average) total dose for rescue pain medication (mg) by study day timeframe as an efficacy measure of OLP-1002 in each dose arm.	Baseline to end of study treatment up to 30 days
Stage 2: Efficacy of OLP-1002 doses (1 ug and 2 ug) in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through average use of rescue pain medication	Measured by the mean (average) total dose for rescue pain medication (mg) by study day timeframe as an efficacy measure of OLP-1002 in each dose arm.	From Baseline to end of study treatment up to 43 days
Stage 1: Efficacy of OLP-1002 doses in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through average total dose for rescue pain medication (mg) by study day timeframe	Measured by the average (mean) total dose for rescue pain medication (mg) by study day timeframe as an efficacy measure of OLP-1002 in each dose arm	Baseline to end of study treatment up to 30 days
Stage 2: Efficacy of OLP-1002 doses (1 ug and 2 ug) in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through average total dose for rescue pain medication (mg) by study day timeframe	Measured by the average (mean) total dose for rescue pain medication (mg) by study day timeframe as an efficacy measure of OLP-1002 in each dose arm	Baseline to end of study treatment up to 43 days
Stage 1: Efficacy of OLP-1002 doses in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through time to first use of rescue pain medication	Measured by the time to first use of rescue pain medication as an efficacy measure of OLP-1002 in each dose arm. It reflects the lasting period of analgesic efficacy of OLP-1002.	Baseline to end of study treatment up to 30 days
Stage 2: Efficacy of OLP-1002 doses (1 ug and 2 ug) in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through time to first use of rescue pain medication	Measured by the time to first use of rescue pain medication as an efficacy measure of OLP-1002 in each dose arm. It reflects the lasting period of analgesic efficacy of OLP-1002.	Baseline to end of study treatment up to 43 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through Treatment-related AEs and serious adverse events (SAEs)	Number of participants with treatment-related adverse events as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) criteria, v5.0.	From baseline to end of study treatment up to 43 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through physical examination abnormalities.	Any abnormalities in the body System observed by the study physician in general appearance, Ears/Eyes/Nose/Throat/Thyroid, Head, Heart, Lungs, Abdomen, Skin, Neurological, Extremities, Back, Neck, Lymph Nodes, Dentition, Nusculoskeleton. For example,; Vital signs: out of range of normal BP systolic BP (lower than 90 and higher than 140), diastolic BP (lower than 40 and higher than 90), PR (50 -100), RR (10-20), BT(96-100 deg F); abnormal clinical exam noted by physical examining investigator.; out of range of normal criteria of ECG parameters.	From baseline to end of study treatment up to 43 days (on the exam dates and lab reported dates)
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through vital signs- blood pressure	Measured by result of the Vital Sign- blood pressure (systolic and diastolic)	From baseline to end of study treatment up to 43 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through vital signs- pulse rate	Measured by result of the Vital Sign- pulse rate	From baseline to end of study treatment up to 43 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through vital signs- respiratory rate	Measured by result of the Vital Sign-respiratory rate	From baseline to end of study treatment up to 43 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through vital signs- oral aural temperature	Measured by result of the Vital Sign- oral aural temperature	From baseline to end of study treatment up to 43 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through injection site reactions.	Measured by result of adverse events recorded as injection site reactions	From baseline to end of study treatment up to 43 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in knee and/or hip through changes in BMI.	Measured by body weight in kilograms (kg) and body height (centimetres) and body weight (kilograms). BMI will be calculated by dividing the participant's body weight in kilograms by the participant's height in meters squared (kg/m2).	From screening visit till the end of the study visit up to 43 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in knee and/or hip joint through through Electrocardiogram (ECG), combination of the Q wave, R wave and S wave (QRS complex)	Measured by QRS interval in ECG	From screening visit till the end of the study visit up to 43 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in knee and/or hip joint through ECG, start of atrial depolarization to start of ventricular depolarization (PR interval)	Measured by PR interval in ECG	From screening visit till the end of the study visit up to 43 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through Electrocardiogram (ECG), time from start of Q wave to end of T wave (QT interval).	Measured by QTcF result in ECG	From screening visit till the end of the study visit up to 43 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through clinical Biochemistry results	Measured by clinically significant changes in Biochemistry results from previous results and out of range of laboratory results for the safety issue. There is no biomarker up to now for the evaluation of the pain reduction unfortunately. The clinical Biochemistry includes AST(U/L), ALT (U/L), GGT (IU/L), ALP (U/L), creatine kinase (U/L), amylase (U/L), serum lipase (U/L), total bilirubin (umol/L), blood urea nitrogen (mg/dL), creatine (umol/L), eGFR (mL/min/1.7 3m^2), uric acid (mmol/L), albumin (g/L), urine albumin/creatinine ratio (ug/mg Cr), total protein (g/L), glucose (mmol/L), cholesterol (mg/dL), triglycerides (mmol/L), potassium (mmol/L), sodium (mmol/L), calcium (mmol/L).	From baseline to end of study visit up to 43 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through clinical hematology results	Measured by clinically significant changes in hematology results from previous results and out of range of laboratory results for the safety issue. Clinical hematology includes hemoglobin(g/L), hematocrit (%), red blood cell count (10^12/L), erythrocyte sedimentation rate (mm/hr), mean cell hemoglobin (pg), mean cell volume(fL), mean cell hemoglobin concentration (g/L), white blood cell count (10^9/L), platelet blood count (10^9/L), and differential blood count (automated).	From baseline to end of study visit up to 43 days
Stage 2: Safety of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through clinical urinalysis	Measured by clinically significant changes in urinalysis results from previous results and out of range of laboratory results for the safety issue. The clinical urinalysis includes nitrites (negative), leukocytes (WBCs/uL), protein (mg/dL), glucose (mg/dL), ketones (mg/dl), blood (RBCs/uL), negative common logarithm of hydrogen ion concentration (pH), specific gravity (1.005 ~1.030), creatinine (mmoL), bilirubin (mg/dL), and urobilinogen (mg/dL).	From baseline to end of study visit up to 43 days
Stage 2: Efficacy of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through reduction in use of allowed rescue pain medication	Compared with Baseline at least 50% reduction in use of allowed rescue pain medication	During Days 1 (postdose) to 4, Days 5 to 8, Days 9 to 15, Days 16 to 22, Days 23 to 29, Days 30 to 36 and Days 37 to 43.
Stage 2: Efficacy of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through change in KOOS Symptoms and QoL Subscale	Change from Baseline in KOOS Symptoms and QoL Subscale: For Symtpom questions S1,2,3, using "Never (0), Rarely (1), Sometimes (2), Often (3), Always (4)" or S4,5 " Always (0), Often (1), Sometimes (2), Rarely (3), Never (4). For QoL comes with corresponding to " Never (0), Monthly (1), Daily (3), Constantly (4)" or Not at all (0), Mildly (1), Moderate (2), Severely (3), Totally or extremely (4)".	On Days 8, 15, 22, 29, 36 and 43 after administration of OLP-1002.
Stage 2: Efficacy of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through change in HOOS Symptoms and QoL Subscale	Change from Baseline in HOOS Symptoms and QoL Subscale: For Symptom question S1,2,3 using "Never (0), Rarely (1), Sometimes (2), Often (3), Always (4)". For Quality of Life comes with corresponding to " Never (0), Monthly (1), Weekly (2), Daily (3), Constantly (4)" or "Not at all (0), Mildly (1), Moderately (2), Severely (3), Totally or extremely (4)" for severity	On Days 8, 15, 22, 29, 36 and end of study visit day 43 after administration of OLP-1002.
Stage 2: Efficacy of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through Brief Pain Inventory questionnaire	Brief Pain Inventory-Short Form (BPI-SF) is a 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. Patient's pain improvement will be assessed after administration of OLP-1002 on a 0 to 10 scale with 0 indicating 'no pain' and 10 indicating 'pain as worse' to assess daily pain scores.	Days 4, 8, 15, 22, 29, 36 and end of study visit day 43 after administration of OLP-1002.
Stage 2: Efficacy of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through Patient Global Impression of Change questionnaire (PGIC)	Patient's pain improvement will be evaluated based on changes in PGIC questionnaire after administration of OLP-1002 into patient with Osteoarthritis to evaluate the condition of subjects activity limitations, symptoms, emotions and overall quality of life. Patient has to chose one answer to 7 questions, each question is measured on a scale from 1 (no change/or condition has gotten worse) to 7 (condition a great deal better/considerable improvement).	Days 4, 15, 22, 29, 36, and end of study visit day 43 after administration of OLP-1002.
Stage 2: Efficacy of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through changes in Western Ontario and McMaster Osteoarthritis Index (WOMAC)	Measured by Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale	Days 4, 8, 15, 22, 29, 36 and end of study visit day 43 after administration of OLP-1002.
Stage 2: Efficacy of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through changes in Visual Analogue Scale (VAS)	Measured by worst daily pain intensity score on a 0 to 10 VAS scale with 0 indicating 'no pain' and 10 indicating 'pain as worse' to assess daily pain scores. Participants will be provided with the Patient Diary to capture daily pain intensity in a 24 hour period.	Baseline to end of study visit day 43 after administration of OLP-1002.
Stage 2: Efficacy of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through changes in the use of rescue pain medication	Measured by rescue pain medication use by study day timeframe	Baseline to end of study visit day 43 after administration of OLP-1002.
Stage 2: Efficacy of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through average use of rescue pain medication	Measured by the mean (average) total dose for rescue pain medication (mg) by study day timeframe.	Baseline to end of study visit day 43 after administration of OLP-1002.
Stage 2: Efficacy of OLP-1002 (1μg and 2μg) compared to placebo in adults with moderate to severe pain due to osteoarthritis in a knee and/or hip joint through time to first use of rescue pain medication	Measured by the time to first use of rescue pain medication	Baseline to end of study visit day 43 after administration of OLP-1002.

Collaborators and Investigators

• Sponsor: OliPass Corporation
• Collaborators: Novotech (Australia) Pty Limited
• Investigators: Principal Investigator: Andrew Ostor, Emeritus Research

Study record dates

Study Major Dates

• Study Start (Actual): January 11, 2021
• Primary Completion (Anticipated): May 31, 2023
• Study Completion (Anticipated): September 30, 2023

Study Registration Dates

• First Submitted: December 20, 2021
• First Submitted That Met QC Criteria: January 18, 2022
• First Posted (Actual): January 31, 2022

Study Record Updates

• Last Update Posted (Estimate): January 16, 2023
• Last Update Submitted That Met QC Criteria: January 12, 2023
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis
• Other Study ID Numbers: OLP-1002-002A

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No